NEW YORK, Dec. 3 — Gene Prot and Waters announced Monday an agreement to equip GeneProt’s new industrial-scale proteomics facility.

Waters, through its subsidiary Micromass UK, will buy a maximum of $10 million of equity securities in GeneProt. The proteomics company will in turn purchase from Micromass about $20 million in mass spectrometry machines and services. The two companies will also collaborate on product development for these instruments.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.